Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.36 |
| ▸ | HTR2A | P28223 | 4/20 | 0.33 |
| ▸ | HTR2C | P28335 | 4/20 | 0.33 |
| ▸ | HTR2B | P41595 | 4/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22856073 | 0.84 | SMN1; SMN2 (0.41) | HRH3PIK3CDHTR2AHTR2CHTR2B | |
| SCHEMBL23696290 | 0.83 | ALDH1A1 (0.41) | HRH3HTR2AHTR2CHTR2BSIGMAR1 | |
| SCHEMBL25071623 | 0.81 | HRH3 (0.42) | HRH3PIK3CDCYP2D6SMN1; SMN2KDM4E | |
| SCHEMBL10151225 | 0.81 | PIK3CD (0.42) | PIK3CD | |
| SCHEMBL26741833 | 0.81 | HRH3 (0.38) | HRH3PIK3CDCYP2D6ALDH1A1 | |
| SCHEMBL21107631 | 0.81 | DRD2 (0.39) | HRH3PIK3CDHTR2AHTR2CHTR2B | |
| SCHEMBL24508530 | 0.80 | DRD2 (0.38) | HRH3PIK3CDHTR2AHTR2CHTR2B | |
| SCHEMBL22309866 | 0.79 | HRH3 (0.41) | HRH3PIK3CDCYP2D6SMN1; SMN2KDM4E | |
| SCHEMBL23696529 | 0.79 | HRH3 (0.41) | HRH3PIK3CDCYP2D6SMN1; SMN2KDM4E | |
| SCHEMBL22526285 | 0.78 | CARM1 (0.40) | HRH3PIK3CDHTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234936-A1 | COMPOUND FOR TARGETING AND DEGRADING PROTEIN, AND PREPARATION METHOD THEREFOR AND USE THEREOF | LEADINGTAC PHARMACEUTICAL (SHAOXING) CO., LTD. (CN) | 2023-07-27 | — | — | US | disclosed |
| US-11352350-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234936-A1 | COMPOUND FOR TARGETING AND DEGRADING PROTEIN, AND PREPARATION METHOD THEREFOR AND USE THEREOF | IRAK4, IRAK2, IRAK1 | HRH3 3945/4885PIK3CD 421/4885HTR2A 4667/4885 |
| US-11352350-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | HRH3 3631/4885PIK3CD 321/4885HTR2A 3621/4885 |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | HRH3 3631/4885PIK3CD 321/4885HTR2A 3621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.